|Furiex Pharmaceuticals, Inc.|
3900 Paramount Parkway
United States - Map
Furiex Pharmaceuticals, Inc. operates as a drug development company that is involved in compound development and collaboration activities primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company holds rights to royalties and regulatory and sales-based milestone payments for alogliptin, alogliptin combination products, and SYR-472 (trelagliptin) for the treatment of Type-2 diabetes, which are marketed under the Nesina and Liovel names in Japan, as well as under the Nesina, Oseni, and Kazano names in the United States. It also owns rights to royalties and sales-based milestones for Priligy (dapoxetine) for premature ejaculation, which is marketed in approximately 30 countries in Europe, the Asia-Pacific, and Latin America. In addition, the company holds license rights to eluxadoline (MuDelta), a novel, orally active, investigational agent, which is in Phase III development diarrhea-predominant irritable bowel syndrome, and to JNJ-Q2, a novel, fluoroquinolone antibiotic, which is in Phase III development for skin and lung infections. It markets its products through third party collaborators. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.
|Furiex Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 4. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 3; Compensation: 5.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. June S. Almenoff M.D., Ph.D., F.A.C.P.,
Pres, Chief Medical Officer and Director
|Mr. Sailash I. Patel ,
Chief Financial Officer, Principal Accounting Officer and VP of Strategic Devel.
|Dr. Paul S. Covington M.D.,
Sr. VP of Clinical Devel. & Operations
|Dr. Gail F. McIntyre Ph.D., CH (ASCP), DABT,
Sr. VP of Research
|Dr. Nadine C. Chien Ph.D., Esq.,
VP of Legal Affairs and Sec.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|